2378

NEW ZEALAND GAZETTE, No. 100

commencing upon receipt of his resignation from the Health Practitioners Disciplinary Tribunal.

Dated at Wellington this 9th day of May 2005.

ANNETTE KING, Minister of Health.

go3980

Appointments to the Medical Radiation Technologists Board

Pursuant to section 221 of the Health Practitioners Competence Assurance Act 2003, I appoint

Iola Calkin

Prue Lamerton

to the Medical Radiation Technologists Board for terms of office commencing from the date of this notification and ending on 30 September 2006.

Dated at Wellington this 27th day of May 2005.

ANNETTE KING, Minister of Health.

go3979

Restricted Activities Under the Health Practitioners Competence Assurance Act 2003

On 27 June 2005, the Health Practitioners Competence Assurance (Restricted Activities) Order 2005 was made by the Governor-General, pursuant to section 9 of the Health Practitioners Competence Assurance Act 2003 (“the HPCAA”).

Formal notification of that Order in Council appears at page 2396 of this New Zealand Gazette.

What are restricted activities? What does this mean for you?

Section 9 of the HPCAA allows for specified activities to be restricted to registered health practitioners, in order to protect members of the public from the risk of serious or permanent harm.

From 1 August 2005, it will be illegal for anyone other than a health practitioner registered under the HPCAA to perform any of the activities listed below. It is an exception to this if the activity is performed in an emergency situation.

30 JUNE 2005

Any breaches will be investigated by the Ministry of Health and may be prosecuted. Anyone found guilty on summary conviction faces a fine of up to $30,000.

What restrictions are being put in place?

The restricted activities that are to be declared under the HPCAA are:

(a) Surgical or operative procedures below the gingival margin or the surface of the skin, mucous membranes or teeth.

(b) Clinical procedures involved in the insertion and maintenance of fixed and removable orthodontic or oral and maxillofacial prosthetic appliances.

(c) Prescribing of enteral or parenteral nutrition where the feed is administered through a tube into the gut or central venous catheter.

(d) Prescribing of an ophthalmic appliance, optical appliance or ophthalmic medical device intended for remedial or cosmetic purposes or for the correction of a defect of sight.

(e) Performing a psychosocial intervention with an expectation of treating a serious mental illness without the approval of a registered health practitioner.

(f) Applying high velocity, low amplitude manipulative techniques to cervical spinal joints.

Further information

This list will shortly be published on the Ministry of Health web site at

www.moh.govt.nz/hpca

This will be supplemented shortly by explanatory material that assists to clarify the intended scope and intention of these restrictions.

A key consideration is that the restrictions are not intended to restrict the activities of practitioners of established professions not regulated under the HPCAA, from carrying out activities that they are currently legitimately doing without risk of harm to the public.

go4111

Medicines Act 1981

Consent to the Distribution of a Changed Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicine which was referred to the Minister of Health under the provisions of section 24 (5) of the Act and is set out in the Schedule hereto:

Schedule

Product: Kogenate FS

Active Ingredient: Octocog alfa 1,000IU

Dosage Form: Powder for injection

New Zealand Sponsor: Bayer New Zealand Limited Pharmaceutical Division

Manufacturer: Bayer Corporation, Biological Products, Berkeley, California, United States of America

Product: Kogenate FS

Active Ingredient: Octocog alfa 250IU

Dosage Form: Powder for injection

New Zealand Sponsor: Bayer New Zealand Limited Pharmaceutical Division

Manufacturer: Bayer Corporation, Biological Products, Berkeley, California, United States of America

Product: Kogenate FS

Active Ingredient: Octocog alfa 500IU

Dosage Form: Powder for injection

New Zealand Sponsor: Bayer New Zealand Limited Pharmaceutical Division

Manufacturer: Bayer Corporation, Biological Products, Berkeley, California, United States of America